Home › Autoimmune Diseases › Texas
Autoimmune Diseases clinical trials in Texas
22 studies for Autoimmune Diseases are looking for participants at sites in Texas.
Cities in Texas
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06817889Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Novel Research LLC, Bellaire
- Arthritis Care of Texas, Corpus Christi
- Precision Comprehensive Clinical Research Solutions, Euless
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07621809A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 25, 2026 · NCT07541287Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT06722235RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients, Dallas
- Houston Methodist Hospital - Accepting Adult Patients, Houston
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients, Houston
RecruitingPhase 2/3
Ages 6 to 75 · All sexes · Updated Sep 17, 2026 · NCT06154252Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
- University of Texas - Houston, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07103746A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
- GSK Investigational Site, Houston
- GSK Investigational Site, Temple
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06572384RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 17, 2026 · NCT06858319Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
Recruiting
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT07759115RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Baylor College of Medicine Neurology Department, Houston
- Houston Methodist Hospital, Houston
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Aug 13, 2026 · NCT06359041A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- UT Southwestern Medical Center, Dallas
- Cook Children's Medical Center, Fort Worth
- Texas Children's Hospital/ Baylor College of Medicine, Houston
- and 1 more
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Aug 6, 2026 · NCT06056297Study of BHV-1300 in Graves' Disease
- Site-109, Dallas
- Site-106, Houston
- Site-101, Houston
- and 1 more
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jul 31, 2026 · NCT06980649Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1003, Dallas
- Site Number - 1047, Denton
- Site Number - 1057, Houston
- and 1 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
- Houston Methodist Hospital, Houston
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Jul 29, 2026 · NCT06193889A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Medical City Dallas, Dallas
- Children's Medical Center Dallas, Dallas
- Zachary & Elizabeth Fisher Bone Marrow Transplant Program (Brooke Army Medical Center), Fort Sam Houston
- and 5 more
RecruitingObservational study
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated May 29, 2026 · NCT04422912Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT04751396Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
- MD Anderson Cancer Center, Houston
- The University of Texas Health Science Center at Houston, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 15, 2026 · NCT06434363A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- UT Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 25, 2026 · NCT06626919From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.